Member Info for markbantam

The name change follows the completion of the sale of Abrdn’s European Private Equity business to Patria Investments, a global alternative asset manager.

https://www.moneymarketing.co.uk/news/abrdn-private-equity-opportunities-trust-changes-name-to-patria-private-equity-trust/

Chair Alan Devine said: "Our extensive due diligence into Patria and their commitment to the interests of our shareholders has assured us that the newly-titled Patria Private Equity Trust is well positioned to capitalise on the broader potential of private equity markets for the long term.”

Well he would say that! Let's wait and see. Anyone any thoughts on this change?

Abrdn Private Equity Opportunities Trust (APEO), a FTSE 250 company founded in 2001, has changed its name to Patria Private Equity Trust (PPET).

The name change follows the completion of the sale of Abrdn’s European Private Equity business to Patria Investments, a global alternative asset manager.

https://www.moneymarketing.co.uk/news/abrdn-private-equity-opportunities-trust-changes-name-to-patria-private-equity-trust/

Now renamed as Patria Private PPET.

"the WRAP Retail Offer is 533.75 pence per Share, representing a premium of 0.60% to the cum-income NAV per Share as at 19 February 2024."

I was a bit slow with regard to info on this, only getting the notification yesterday and didn't sign up. The Wrap offer looks like a non event seeing that the share price has fallen toda, practically negating the premium. Did anyone particpate is this/ have any thoughts on this?

Share price rise has been limited by investors knowing that GSK are trying to sell to raise funds for aquisition. Hopefully, they will get sell the remaining 4% later in the year and see where it goes from there. Pfizer don't see to be in any hurry to sell their stake.

Jan 17 (Reuters) - GSK (GSK.L), opens new tab has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon (HLN.L), opens new tab, the British drugmaker said on Wednesday.

GSK sold around 300 million shares in Haleon at 326 pence per share, cutting its shareholding in the world's largest standalone consumer healthcare company to 4.2%

https://www.reuters.com/markets/deals/gsk-sell-32-stake-spin-off-haleon-2024-01-16/

"Consumer goods giant Unilever (ULVR.L) on Monday said it would sell Elida Beauty, its non-core beauty and personal care division, to U.S. private equity firm Yellow Wood Partners.The financial terms of the deal, expected to be completed in mid-2024, were not disclosed. Elida's portfolio comprises of more than 20 beauty and personal care brands including Q-Tips, Brut, Caress, Timotei and Tigi and the business generated about 800 million pounds ($1.02 billion) in revenues in 2022."

https://www.reuters.com/markets/deals/unilever-sell-elida-beauty-yellow-wood-2023-12-18/

Anyones thoughts on this and how this will change the business/share price

Some comments on cloud cover effect on temperatures but this article is probably a good place to start as it looks at the whole energy balance that others don't. https://earthobservatory.nasa.gov/features/EnergyBalance#:~:text=Earth's%20temperature%20doesn't%20infinitely,of%20energy%20radiating%20into%20space.

I was looking at SHED also to diversify my REITs and came up with the same issue on II (Interactive Investor). I can't see any reaosn that SHED is any different to other REITs an as no one has come up wth anything , I assume it is an anomaly.

Further to "meoryou" post a bit more information on the sale to institutional investors.

Reuters "British drugmaker GSK (GSK.L) on Friday sold 240 million shares in its consumer healthcare business Haleon (HLN.L) at 335 pence per share, raising about 804 million pounds ($1 billion)... The sale price represents a 2.3% discount to Haleon's closing price of 342.85 pence on Thursday and lowers the stake of GSK, the second-largest shareholder, to 10.3%... GSK and Pfizer have agreed to not sell any further Haleon shares for 60 days."

In another article on Fierce Pharma websit "Just last week, Pfizer, which has a 32% stake in Haleon, told the Financial Times that it would begin a “slow and methodical” sale of its holdings.“We love the Haleon business but it's not strategic,” Pfizer’s chief financial officer Dave Denton . Pfizer’s Haleon stake is worth just over 10 billion pounds ($12.5 billion)."

APEO was included in both theie Active Growth and Active Income Model Portfolios. The annual review has now designated APEO a sell as "To align the Model more closely with the benchmark allocation by reducing unlisted exposure".
This may lead to a sell off and share price fall in the short term. A buying opportunity if this happens! https://www.ii.co.uk/model-portfolios#active-growth

Good spot. Hopefully the results will be in line with expectations and a dividend will be announced, and that might help the share price along. " Analysts expect a 15 per cent increase in turnover to £10.9 billion for 2022, with profits up 5 per cent to £2.3 billion and a dividend of 3p, doubling to 6p this year."

Today Rns anouncing the above partnership is in line with the vision in the November Trading update " We have made good progress in ongoing discussions regarding geographic expansion and continue to explore opportunities for growth in our existing markets as we deliver on our strategy of becoming the protein partner of choice" Hopefully it will conribute to a better 2023

ITM was fortunate to have raised so much cash, but the bubble has burst and shares prices across the sector are where they should be, considering the hydrogen mass market is a long way off . Unfortunately the board including Cooley and an inexperienced Finance Director (Andy Allen no real experience outside ITM) in the commercialisation of new technologies, have got themselves in a position where there are minimal sales and a massive cash burn. I have made the decision to invest elsewhere for the time being and take my profits as i don't see a positive for ITM unless there is a radical change ( or a takeover which I was hoping for and might still happen). I have enjoyed this board for the different views and may be back!. GLA

agreee market cap now £413 million, net assets valued at £394 million including £365 mill cash ( 22 apr 22 lse fundamentals) so presents an opportunity for some.

Entering a takeover territory as my previous posts indicated. Market Cap at 470 million with 350 million in the bank, so cheap buying a business at around £100 million assuming a premium. The management don't deserve to survive, taking millions out in performance payments - reminds me of the TImnbuktu rowing team joke (for those who can remember it although I think its been updated!) .

just been doing a lttle reserach on this. Haleon CEO appears to be taking a firm line
https://www.fiercepharma.com/pharma/haleon-sees-revenue-growth-after-gsk-spin-out-rejects-zantac-litigation-claims

"The decommissioning of ITM Motive refuelling stations is costly and bonkers - they will be needed in the future for net zero so why not inject Gov't financial support ". Perhaps someone in the government asked why should we give money to a company sitting on ~£300 million of cash and has a partner in Shell, who is making massive profits. Let's put that suggestion out to the public who are struggling to pay their utility bills and see if that restores confidence in us?

Resign - some chance! the four executive directors remuneration was over £10 million in 2022, based on sales of £5 million. That was on top of their £7 million remuneration in 2021. Plenty of opportunity for them to trouser some more, managing the money raised to build the "not needed" factory. Hydrogen has a future but not with this lot.

All the hydrogen stocks are fallling but ITM worse than others. Is the future a takeover? getting close to 75p when all the cash , assets and the technology looks attractive and with better mnagement who knows what th efuture will bring.

Now below 100p and maybe heading to the 75-90p range that I mentioned the other day, which I think is a good buy in as it makes an attrctive takeover target. ITM managment, sales, production etc is a mess and needs to be out of its misery.